Older people with visual impairment can report feeling dizzy and falling. A new study found that after routine cataract surgery, the improved vision led to patients experiencing significantly less…
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
Status: Not yet recruiting,
Condition Summary: Dry Eye Syndromes
Uncategorized
AAO launches effort to rebrand itself as vanguard of eye care
The American Academy of Ophthalmology is embarking on an initiative to rebrand itself and foster an understanding of the specialty’s impact on society, a speaker said at the AAO annual meeting in Las Vegas.AAO CEO David W. Parke II, MD, described the rebranding effort during a press briefing. Although the initiative will involve changes to the AAO’s logo, tagline, design of products and website, it is mainly designed to enhance the public’s understanding of the goals and contributions of ophthalmology, Parke said.
FDA Ruffles Feathers by Delaying DMD Tx Review
(MedPage Today) — Eteplirsen review pushed to 2016, while drisapersen reviewed as scheduled
Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman, will participate in a fireside chat presentation at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015 at 9:30 a.m. ET at The New York Palace Hotel in New York C
Uncategorized
AGTC receives orphan drug designation for gene therapy to treat achromatopsia
The FDA has granted orphan drug designation to AGTC’s gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene, AGTC announced in a press release. “Receiving U.S. orphan drug designation is another significant milestone as we continue to advance our pipeline of novel gene therapies to treat rare inherited eye disorders,” Sue Washer, president and CEO of AGTC, said in the release.